Immune globulin - Grifols

Drug Profile

Immune globulin - Grifols

Alternative Names: Flebogamma 10% DIF; Flebogamma 5% DIF; Flebogamma DIF; GamaSTAN S/D; IGSC 20% - Grifols; Immune Globulin Subcutaneous 20% Caprylate/Chromatography; Intravenous normal Human immunoglobulin – Grifols; IVIG - Grifols; Xepol; XS-28

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Grifols
  • Class Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postpoliomyelitis syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Guillain-Barre syndrome; Hepatitis A; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Measles; Rubella; Varicella zoster virus infections
  • Registered Mucocutaneous lymph node syndrome
  • Phase III Alzheimer's disease
  • Phase II/III Postpoliomyelitis syndrome

Most Recent Events

  • 01 Dec 2017 Grifols Therapeutics completes a phase III trial for Immunodeficiency disorders (In children, In adolescents, In adults, In the elderly) USA and Canada (SC) (NCT02604810)
  • 12 May 2016 Phase-III clinical trials in Immunodeficiency disorders (In children, In adults, In adolescents) in United Kingdom, Spain (SC) (EudraCT2015-003290-15)
  • 18 Nov 2015 Grifols Therapeutics plans a phase III trial for Immunodeficiency disorders (In children, In adolescents, In adults) USA (SC) (NCT02604810)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top